Compare ASML & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASML | JNJ |
|---|---|---|
| Founded | 1984 | 1886 |
| Country | Netherlands | United States |
| Employees | 44209 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.7B | 589.2B |
| IPO Year | N/A | 2003 |
| Metric | ASML | JNJ |
|---|---|---|
| Price | $1,430.48 | $225.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $1,460.63 | $238.20 |
| AVG Volume (30 Days) | 1.7M | ★ 6.9M |
| Earning Date | 04-15-2026 | 04-14-2026 |
| Dividend Yield | 0.51% | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $17.80 | $6.63 |
| Revenue Next Year | $19.51 | $7.43 |
| P/E Ratio | ★ $50.62 | $106.51 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $651.46 | $146.12 |
| 52 Week High | $1,547.22 | $251.71 |
| Indicator | ASML | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 32.61 |
| Support Level | $1,285.49 | $201.37 |
| Resistance Level | $1,524.40 | $246.40 |
| Average True Range (ATR) | 44.49 | 4.72 |
| MACD | -0.96 | -1.34 |
| Stochastic Oscillator | 33.26 | 6.12 |
ASML is the leader in lithography systems for manufacturing semiconductors with 90% market share. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's largest clients are TSMC, Samsung, and Intel.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.